Intech Investment Management LLC Increases Position in Hims & Hers Health, Inc. $HIMS

Key Points

• Intech Investment Management LLC increased its stake in Hims & Hers Health by 74.5%, owning 143,287 shares valued at approximately $4.2 million after acquiring an additional 61,195 shares.
• Several hedge funds, including New York State Teachers Retirement System and Fifth Third Bancorp, made significant increases in their holdings of Hims & Hers Health during the first quarter, indicating strong institutional interest.
• Hims & Hers Health recently reported a loss of $0.01 per share for Q2, missing analyst expectations, although its revenue increased 72.6% year-over-year to $544.83 million.

Intech Investment Management LLC increased its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 74.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 143,287 shares of the company's stock after acquiring an additional 61,195 shares during the period. Intech Investment Management LLC owned approximately 0.06% of Hims & Hers Health worth $4,234,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of HIMS. Nuveen LLC bought a new stake in Hims & Hers Health during the first quarter worth about $58,403,000. Yong Rong HK Asset Management Ltd boosted its stake in Hims & Hers Health by 41.2% during the first quarter. Yong Rong HK Asset Management Ltd now owns 2,400,000 shares of the company's stock worth $70,920,000 after acquiring an additional 700,100 shares in the last quarter. CloudAlpha Capital Management Limited Hong Kong bought a new stake in Hims & Hers Health during the first quarter worth about $20,580,000. Jump Financial LLC boosted its stake in Hims & Hers Health by 633.2% during the first quarter. Jump Financial LLC now owns 725,445 shares of the company's stock worth $21,437,000 after acquiring an additional 626,496 shares in the last quarter. Finally, Two Sigma Investments LP boosted its stake in Hims & Hers Health by 37.9% during the fourth quarter. Two Sigma Investments LP now owns 1,967,354 shares of the company's stock worth $47,571,000 after acquiring an additional 540,274 shares in the last quarter. Institutional investors own 63.52% of the company's stock.

Hims & Hers Health Stock Performance

Shares of HIMS traded up $5.68 during mid-day trading on Thursday, hitting $56.03. 19,085,738 shares of the company traded hands, compared to its average volume of 33,086,945. Hims & Hers Health, Inc. has a 1 year low of $15.73 and a 1 year high of $72.98. The stock has a market cap of $12.66 billion, a price-to-earnings ratio of 69.98, a P/E/G ratio of 3.44 and a beta of 2.14. The company has a debt-to-equity ratio of 1.72, a quick ratio of 4.46 and a current ratio of 4.98. The stock has a 50-day moving average price of $50.40 and a two-hundred day moving average price of $45.43.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its earnings results on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The business had revenue of $544.83 million for the quarter, compared to analysts' expectations of $550.06 million. During the same period in the prior year, the company posted $0.06 earnings per share. The firm's quarterly revenue was up 72.6% on a year-over-year basis. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Analyst Ratings Changes

HIMS has been the topic of several research reports. Wall Street Zen downgraded shares of Hims & Hers Health from a "buy" rating to a "hold" rating in a research note on Monday, July 28th. Canaccord Genuity Group reiterated a "buy" rating and issued a $68.00 target price on shares of Hims & Hers Health in a research note on Friday, September 12th. Needham & Company LLC reiterated a "hold" rating on shares of Hims & Hers Health in a research note on Tuesday, August 5th. Citigroup reiterated a "sell" rating on shares of Hims & Hers Health in a research note on Monday, June 23rd. Finally, Truist Financial dropped their target price on shares of Hims & Hers Health from $48.00 to $37.00 and set a "hold" rating on the stock in a research note on Monday, August 18th. Two research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have given a Sell rating to the company's stock. Based on data from MarketBeat.com, Hims & Hers Health has a consensus rating of "Reduce" and a consensus price target of $38.92.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, CEO Andrew Dudum sold 128,127 shares of the company's stock in a transaction that occurred on Tuesday, September 16th. The shares were sold at an average price of $53.48, for a total transaction of $6,852,231.96. Following the completion of the sale, the chief executive officer directly owned 160,425 shares of the company's stock, valued at approximately $8,579,529. This represents a 44.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Soleil Boughton sold 2,571 shares of the company's stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $44.53, for a total transaction of $114,486.63. Following the sale, the insider directly owned 150,450 shares of the company's stock, valued at approximately $6,699,538.50. This represents a 1.68% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,435,158 shares of company stock valued at $72,985,050 in the last quarter. Insiders own 13.71% of the company's stock.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.